Russian Heart Failure Journal 2008year Effects of spironolactone and digoxin on prognosis in patients with CHF. Results of a 30-year follow-up

To access this material please log in or register

Register Authorize

Effects of spironolactone and digoxin on prognosis in patients with CHF. Results of a 30-year follow-up

Petrukhina A.A., Mareev V.Yu., Skvortsov A.A., Belyavsky E.A., Kheymets G.I., Belenkov Yu.N.



Urgency. The nature of pharmacotherapy is the most important factor influencing the course and outcome of CHF. Digoxin and spironolactone, the oldest agents for the treatment of CHF may influence the prognosis. Aim. To study the effect of digoxin and spironolactone as a part of multimodality treatment on prognosis in patients with CHF by data of a post hoc study. Materials and methods. The study retrospectively analyzed 1118 case reports of patients with signs of clinically pronounced heart failure (II–IV NYHA FC) who were admitted in the Myasnikov Institute of Clinical Cardiology from 1977 to 1986, from 1987 to 1996, and from 1997 to 2005. Effects of different factors (including digoxin and spironolactone therapy) on long-term prognosis of patients were evaluated. Results. The enhanced neuro-hormonal blockade by addition of spironolactone to the baseline therapy with β-adrenoblocklers and ACEI was not associated with further improvement of prognosis in patients with CHF but rather resulted in a 19% increment of relative risk (RR) for death. At the same time, prognosis of patients receiving spironolactone directly depended on the dose of medicine. In patients receiving spironolactone 12.5–50 mg, RR of death was 14.4 % lower than in patients receiving 75–100 mg. The highest RR of death was observed in patients receiving maximal doses of verospiron (150–400 mg), even compared with patients receiving moderate doses of the aldosterone antagonist. Analysis of the effect of digoxin on prognosis in patients with CHF showed that survival of patients with sinus rhythm depended on the dose of medicine and was significantly better in patients taking ≤0.25 mg of digoxin daily (death RR reduction 42 %; 95 % CI 2.1 %-96.7 %, р=0.035) than in patients taking higher doses of cardiac glycosides. Therefore the treatment with spironolactone in doses higher than 50 mg/day and digoxin in doses higher than 0.25 mg/day as a part of multimodality therapy in combination with ACEI and β-adrenoblockers adversely affects prognosis of patients with clinically pronounced CHF in the setting of routine clinical practice.
    1.    Мареев В. Ю., Беленков Ю. Н., Агеев Ф. Т., Фомин И. В. и др. Первые результаты Российского эпидемиологического исследования по ХСН (ЭПОХА-ХСН). Журнал Сердечная недостаточность. 2003;4 (1):17–18.
    2.    Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347 (18):1397–1402.
    3.    Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. Медикаментозные пути улучшения прогноза больных хронической сердечной недостаточностью. – М:, Инсайт. 1997, – 69–72.
    4.    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316 (23):1429–1435.
    5.    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325 (5):293–302.
    6.    Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. (COPERNICUS). N Engl J Med. 2001;344 (22):1651–1658.
    7.    MERIT-HF Study Group. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomised Intervention Trial in Heart Failure (MERIT-HF). Lancet. 1999;353 (9169):2001–2007.
    8.    CIBIS – II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS – II): a randomized trial. Lancet. 1999;353 (9146):9–13.
    9.    Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348 (14):1309–1321.
    10.    Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717.
    11.    Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351 (6):543–551.
    12.    The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336 (8):525–533.
    13.    Fonarow GC, Yancy CW, Heywood JT et al. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med. 2005;165 (13):1469–1477.
    14.    Brophy JM. Rehabilitating digoxin. Eur Heart J. 2006;27 (2):127–129.
    15.    Pitt B. Whither withering? The role of digoxin in patients with heart failure due to systolic left ventricular dysfunction in sinus rhythm. J Card Fail. 2006;12 (5):347–348.
    16.    Ali Ahmed, Rich MW, Love TE et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27 (2):178–186.
    17.    Ahmed A, Pitt B, Rahimtoola SH et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. 2008;123 (2):138–146.
    18.    Svensson M, Gustafsson F, Galatius S et al. Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ. 2003;327 (7424):1141–1142.
    19.    Ko DT, Juurlink DN, Mamdani MM et al. Appropriateness of spironolactone prescribing in heart failure patients: a population based study. J Card Fail. 2006;12 (3):205–210.
    20.    Wrenger E, Muller R, Moesenthin M et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327 (7407):147–149.
    21.    Schepkens H, Vanholder R, Billiouw JM et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110 (6):438–441.
    22.    Uretsky BF, Young JB, Shahidi FE et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED Trial. J Am Coll Cardiol. 1993;22 (4):955–962.
    23.    Packer M, Gheorghiade M, Young JB et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993;329 (1):1–7.
    24.    Adams KF, Patterson JH, Gattis WA et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46 (3):497–504.

To access this material please log in or register

Register Authorize
Ru En